9-Valent human papillomavirus vaccine: a review of the clinical development program. (2nd November 2017)

• Record Type: Journal Article
• Authors: Luxembourg, Alain; Moeller, Erin
• Is Part Of: Expert review of vaccines. Volume 16:Number 11(2017)
• Page Start: 1119
• Page End: 1139
• Publication Date: 2017-11-02
• Subjects: Cervical cancer -- genital warts -- human papillomavirus -- vaccine -- 9-valent; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1080/14760584.2017.1383158
• Languages: English
• ISSNs: 1476-0584

Abstract

ABSTRACT: Introduction : The 9-valent human papillomavirus (9vHPV) vaccine covers the same HPV types (6/11/16/18) as the quadrivalent HPV (qHPV) vaccine and 5 additional cancer-causing types (31/33/45/52/58). Epidemiological studies indicate that the 9vHPV vaccine could prevent approximately 90% of cervical cancers, 70–85% of high-grade cervical dysplasia (precancers), 85–95% of HPV-related vulvar, vaginal, and anal cancers, and 90% of genital warts. Areas covered : Study design features and key findings from the 9vHPV vaccine clinical development program are reviewed. In particular, 9vHPV vaccine efficacy was established in a Phase III study in young women age 16–26 years. Efficacy results in young women were extrapolated to pre- and young adolescent girls and boys and young men by immunological bridging (i.e., demonstration of non-inferior immunogenicity in these groups versus young women). Expert commentary : The development of the 9vHPV vaccine is the outcome of 20 years of continuous clinical research. Broad vaccination programs could help substantially decrease the incidence of HPV-related disease.